SCHEMBL273223

SCHEMBL273223

COc1ccc(C(=O)Nc2ccccc2C(=O)N/N=C/c2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.67
KDM4E B2RXH2 6/20 0.67
HPGD P15428 5/20 0.67
PKM P14618 5/20 0.67
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
ALOX12 P18054 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67
NPC1 O15118 8/20 0.64
RAB9A P51151 8/20 0.64
ALDH1A1 P00352 3/20 0.64
POLB P06746 2/20 0.58
RXFP1 Q9HBX9 1/20 0.52
LMNA P02545 1/20 0.49
MIF P14174 1/20 0.49
OPRK1 P41145 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267846 1.00 MAPT (0.67) MAPTKDM4EHPGDPKMMEN1
SCHEMBL267847 1.00 MAPT (0.67) MAPTKDM4EHPGDPKMMEN1
SCHEMBL265840 0.93 MAPT (0.57) MAPTKDM4EHPGDPKMMEN1
SCHEMBL265839 0.93 MAPT (0.57) MAPTKDM4EHPGDPKMMEN1
SCHEMBL273618 0.93 MAPT (0.57) MAPTKDM4EHPGDPKMMEN1
SCHEMBL268357 0.90 RAB9A (0.66) MAPTKDM4EHPGDPKMMEN1
SCHEMBL268356 0.90 RAB9A (0.66) MAPTKDM4EHPGDPKMMEN1
SCHEMBL273540 0.90 RAB9A (0.66) MAPTKDM4EHPGDPKMMEN1
SCHEMBL273863 0.82 GRM4 (0.57) MAPTKDM4EPKMMEN1KMT2A
SCHEMBL266916 0.82 GRM4 (0.57) MAPTKDM4EPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885KDM4E 4535/4885HPGD 2407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.